MindMed Announces Material Definitive Agreement
Ticker: DFTX · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1813814
| Field | Detail |
|---|---|
| Company | Mind Medicine (Mindmed) Inc. (DFTX) |
| Form Type | 8-K |
| Filed Date | Mar 11, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 8 min |
| Key Dollar Amounts | $6.00, $93.8 m, $70.3 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale
TL;DR
MindMed signed a big deal, filed an 8-K.
AI Summary
Mind Medicine (MindMed) Inc. announced on March 7, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and other events. The filing includes financial statements and exhibits.
Why It Matters
This filing indicates a significant new agreement for MindMed, which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements and unregistered sales of equity can introduce financial and operational risks.
Key Players & Entities
- Mind Medicine (MindMed) Inc. (company) — Registrant
- March 7, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement?
The filing does not specify the details of the material definitive agreement, only that one was entered into on March 7, 2024.
What type of equity securities were sold?
The filing mentions unregistered sales of equity securities but does not provide specific details about the type or amount.
What are the 'Other Events' reported?
The filing lists 'Other Events' as an item but does not provide specific details within the provided text.
When was the report filed?
The report was filed on March 11, 2024.
Where is Mind Medicine (MindMed) Inc. headquartered?
Mind Medicine (MindMed) Inc.'s principal executive offices are located at One World Trade Center, Suite 8500, New York, New York, 10007.
Filing Stats: 1,891 words · 8 min read · ~6 pages · Grade level 13.8 · Accepted 2024-03-11 08:32:03
Key Financial Figures
- $6.00 — (the "Shares"), at an offering price of $6.00 per share, less underwriting discounts
- $93.8 m — fering are expected to be approximately $93.8 million, after deducting underwriting dis
- $70.3 m — cement are expected to be approximately $70.3 million, after deducting fees and expense
Filing Documents
- d787577d8k.htm (8-K) — 40KB
- d787577dex11.htm (EX-1.1) — 233KB
- d787577dex51.htm (EX-5.1) — 8KB
- d787577dex101.htm (EX-10.1) — 171KB
- d787577dex102.htm (EX-10.2) — 142KB
- d787577dex991.htm (EX-99.1) — 10KB
- g787577g0308090836709.jpg (GRAPHIC) — 2KB
- g787577g0308121939029.jpg (GRAPHIC) — 5KB
- 0001193125-24-064380.txt ( ) — 894KB
- mnmd-20240307.xsd (EX-101.SCH) — 2KB
- mnmd-20240307_lab.xml (EX-101.LAB) — 18KB
- mnmd-20240307_pre.xml (EX-101.PRE) — 11KB
- d787577d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements Certain statements in this Current Report on Form 8-K related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential" or "continue", or the negative thereof or similar variations. Forward-looking information in this Current Report on Form 8-K includes, but is not limited to, statements relating to the Offering and the Private Placement, the amount of proceeds expected from the Offering and the Private Placement and the timing and certainty of completion of the Offering and the Private Placement. The risks and uncertainties relating to the Company include risks regarding anticipated upcoming milestones, and progress of trials; timing of a potential End-of-Phase-2 meeting with the FDA; timing of the initiation of a potential Phase 3 clinical trial of MM120; and the potential benefits of the Company's product candidates. There can be no guarantees regarding the results of the potential Phase 3 clinical trial or that, following any such trial, MM120 will receive the necessary regulatory approvals. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance w
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 1.1 Underwriting Agreement, dated March 7, 2024, by and between Mind Medicine (MindMed) Inc. and Leerink Partners LLC and Cantor Fitzgerald & Co. 5.1 Opinion of Osler, Hoskin & Harcourt LLP 10.1 Form of Securities Purchase Agreement, dated as of March 7, 2024 between Mind Medicine (MindMed) Inc. and the Investors 10.2 Form of Registration Rights Agreement, dated as of March 7, 2024 between Mind Medicine (MindMed) Inc. and the Investors 23.1 Consent of Osler, Hoskin & Harcourt LLP (included in Exhibit 5.1) 99.1 Press Release, dated March 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 11, 2024 Mind Medicine (MindMed) Inc. By: /s/ Robert Barrow Name: Robert Barrow Title: Chief Executive Officer